NSAIDs are the chemically diverse class of drugs that have anti-inflammatory, analgesic & antipyretic properties.
They are also called as Non Narcotic, Non Opioid, Aspirin like analgesics.
They are among the widely used therapeutic agents world wide and often taken without prescription for minor aches and pain.
They are used to suppress the symptoms of inflammation associated with rheumatic disease.
NSAIDs are the chemically diverse class of drugs that have anti-inflammatory, analgesic & antipyretic properties.
They are also called as Non Narcotic, Non Opioid, Aspirin like analgesics.
They are among the widely used therapeutic agents world wide and often taken without prescription for minor aches and pain.
They are used to suppress the symptoms of inflammation associated with rheumatic disease.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.for more details please visit
www.indiandentalacademy.com
Classification
Mechanism of action
Duration of action
Absorption and distribution
Mode of action
Theories of action of L.A
Pharmacokinetics of local anaesthetics
Routes of administration
Metabolism or biotransformation
Individual agents
Vasoconstrictors
Systemic effects
Toxicity
Advantages
Disadvantages
Maximum allowable dose
Local anaesthetics in community trust services
A PowerPoint presentation on "NSAIDS" suitable for reading by UG and PG Medical/Paramedical students of Pharmacology and Pharmacy sciences. This Ppt. is prepared for academic purpose only and already presented to my students in one of the theory classes of mine.
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class.Coxibs are NSAIDs that are highly selective for the COX2 enzyme. Because the COX2 enzyme mediates prostaglandin production responsible for inflammation and pain, coxibs are analgesic and antiinflammatory, but they lack the side effects related to inhibiting the COX1 enzyme (e.g., bleeding and gastrointestinal irritation).
Lecture slides for undergraduates medical (MBBS) Students. Source material for this presentation is Essentials of Pharmacology, KD Tripathi, Katzung and Goodman and Gillman. It deals with Local anaesthetics with their mechanism of action, pharmacokinetics , adverse effects and therapeutic uses.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.for more details please visit
www.indiandentalacademy.com
Classification
Mechanism of action
Duration of action
Absorption and distribution
Mode of action
Theories of action of L.A
Pharmacokinetics of local anaesthetics
Routes of administration
Metabolism or biotransformation
Individual agents
Vasoconstrictors
Systemic effects
Toxicity
Advantages
Disadvantages
Maximum allowable dose
Local anaesthetics in community trust services
A PowerPoint presentation on "NSAIDS" suitable for reading by UG and PG Medical/Paramedical students of Pharmacology and Pharmacy sciences. This Ppt. is prepared for academic purpose only and already presented to my students in one of the theory classes of mine.
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class.Coxibs are NSAIDs that are highly selective for the COX2 enzyme. Because the COX2 enzyme mediates prostaglandin production responsible for inflammation and pain, coxibs are analgesic and antiinflammatory, but they lack the side effects related to inhibiting the COX1 enzyme (e.g., bleeding and gastrointestinal irritation).
Lecture slides for undergraduates medical (MBBS) Students. Source material for this presentation is Essentials of Pharmacology, KD Tripathi, Katzung and Goodman and Gillman. It deals with Local anaesthetics with their mechanism of action, pharmacokinetics , adverse effects and therapeutic uses.
the topic contain nonsteroidal antiinflammatory drugs which include, mediatorsof inflammation, cox-1 and cox-2, classification of drugs, its pharmacological effect and adverse reaction of drug.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
3. Introduction
• Antipyretic, Analgesic & Anti-inflammatory drugs
• Grouped in different classes based on there chemical
structures
• Share similar pharmacological effects, mechanism of
action & adverse effects
• Inhibit biosynthesis of Prostaglandins
5. Cox-1 Pathway
• Constitutive → Housekeeping enzyme
• Homeostatic function
• Gastric protection (PGE2 and PGI2)
– ↓ acid production & ↑ mucous production
– ↑ mucosal blood flow so less chances of peptic ulcers
• Regulation of platelet aggregation (PGI2 and TXA2)
• Regulation of renal blood flow (PGI2 and TXA2)
6. • Induced → expression increases during inflammation
• Facilitate inflammatory response & cause fever and pain
• Expressed in brain, vascular endothelium & kidney
• Cox 2 inhibitors ↓ vasodilatation & ↑ platelet aggregation
• Chances of thrombosis are ↑ on prolonged use
• Little GI toxicity
Cox-2 Pathway
8. 1.Antipyretic Effect
• Body temperature regulation
• Only ↓ the body temperature of those who have
fever and no effect on normal ones
• Fever → generation of pyrogens → PGE2 production
in hypothalamus → raise temperature set point
• NSAIDs block action of pyrogens but not of PGE2
9. 2.Analgesic Effect
• Cause of pain: in tissue injury or inflammation
chemical algesiogenic substances
are produced and released such as
bradykinin, TNFα together with PGs
• Bradykinin: cause pain through stimulating the
algesireceptors directly
• PG: Hyperalgesia
PG(E1 E2 F2α) have algesiogenic effect
NSAIDs inhibit the synthesis of PGs in periphery
10. 3.Anti-inflammatory Effect
• Inhibition of PGs synthesis at site of injury
• Activated endothelial cells express adhesion molecules
(ECAM, ICAM) → direct circulating leucocytes to site of
inflammation (chemotaxis)
• Inflammatory cells express selectins & integrins
• Inhibiting expression & activity of these molecules and
generation of superoxide & free radicals
• Inhibit growth factors & lymphocyte transformation factors
11. Other actions of NSAIDS due to inhibition PG
Synthesis
4.Gastric damage
5.Nephropathy
6.Delay labour
7.Closure of ductus arteriosus
8.Precipitation of asthma, due to increase in
lipoxygenase in sensitive individuals.
12. Pharmacokinetics
• Weak organic acids (except Nabumetone → ketone prodrug)
• Metabolized by CYP3A or CYP2C P450 enzymes in liver
• Renal excretion most common along with
biliary excretion & reabsorption
• Highly protein bound (~ 98%)
• Found in synovial fluid after repeated dosing
Drugs with short half lives remain in joints longer
13. Common Adverse Effects
• Platelet Dysfunction
• Gastritis and peptic ulceration with bleeding
• Acute Renal Failure in susceptible
• Sodium and water retention → edema
• Analgesic nephropathy
• Headaches, tinnitus & dizziness
• Hypersensitivity (not immunologic but due to PG inhibition)
16. Aspirin
• Only irreversible inhibitor of Cox enzyme
• At low doses (50- 300 mg) acts as an Antiplatelet drug
– Prophylaxis of MI and stroke
– Reduces transient ischemic attacks
– Colonic polyp
• ↓ TXA2 (platelet aggregator) also ↓ PGI2 (anti aggregatory)
– TXA2 synthesized by platelets is exposed to aspirin in portal circulation
but very little aspirin reaches systemic circulation to inhibit PGI2 synthesis
– Platelets lack nuclei & cannot synthesize new Cox once inhibited but
endothelium regenerate Cox to produce PGI2
• Useful in dysmenorrhoea & pre eclampsia
17. Adverse Effects
• Dose dependent effects on acid base balance
– Respiratory alkalosis occurs at high doses → headache, vertigo, tinnitus,
vomiting & hyperventilation (salicylism)
– Excessive metabolic compensation causes metabolic acidosis → loss of
vision , hyperpyrexia, dehydration, convulsions & coma
– More common in infants
– Treated by supportive measures, gastric lavage, correcting metabolic
acidosis & urine alkalinization to ↑ excretion
• Hyperuricemia
• Prolongs bleeding time
• Reyes syndrome in children (hepatic encephalopathy)
18. Indomethacin
• Inhibits phospholipase A & C
↓ T cell & B cell proliferation
• Potent anti-inflammatory → Gout & Ankylosing spondylitis
• Accelerate closure of PDA
• Headache & sedation common
• Combined with potassium repletion to improve symptoms of
Bartter’s syndrome
19. • 99% protein bound
Good tissue penetrability & conc. in synovial fluid
maintained 3 times longer than in plasma
• Most extensively used NSAID in rheumatoid & osteoarthritis,
bursitis and toothache
• Combined with misoprostol ↓ upper GI ulceration
Combined with omeprazole ↓ recurrent bleeding
• 0.1% preparation → postoperative ophthalmic inflammation
3% preparation → solar keratosis
Diclofenac
20. Other Non selective Cox inhibitors
• Flurbiprofen 5% topical ophthalmic formulation for inhibition of
intraoperative miosis
• Naproxen is long acting that inhibits leucocytes
migration,symptomatic relief in gout.
• Mephenamic acid → PG receptor antagonist + PLPA2 inhibitor
useful in dysmenorrhoea(diarrhoea common adverse effect)
• Ketorolac inhibit Lipoxygenase also,used i.v. for mild to moderate
post surgical pain
• Piroxicam is longest acting NSAID → incidence of peptic ulcer
is 10 times higher than with other NSAIDs
21. Nimesulide
• NSAID with preferential Cox 2 inhibitor
• Anti-inflammatory action :
– inhibition of PAF & TNFα
– ↓ superoxide by neutrophils
– free radical scavenging
– ↓ metalloproteinase activity in cartilage
• Short painful inflammatory conditions like sports injuries,
sinusitis, tooth ache, low backache
• Withdrawn from some countries due to instances of fulminant
hepatic failure
• Pediatric preparations banned in India
22. Selective Cox 2 inhibitors
• Celecoxib, Etoricoxib & Parecoxib
• Advantage of little GI toxicity
• Rofecoxib & Valdecoxib withdrawn due to ↑ risk of MI
• Celecoxib is sulfonamide derivative & cause rash &
hypersensitivity
• Etoricoxib long acting coxib & requires monitoring of hepatic
function
23. Paracetamol (Acetaminophen)
• No anti-inflammatory activity
Best drug to be used as antipyretic
• Very little GI toxicity & can be given to patients
intolerant to other NSAIDs
• Metabolized to N acetyl paraaminobenzo quinone (NAPQ)
→ high affinity for sulfhydryl groups → hepatotoxicity
• Safe drug because glutathione (containing sulfhydryl group)
produced by liver combines with NAPQ to detoxify it
24. Paracetamol
• Chronic alcoholics are predisposed to toxicity because
– Glutathione production ↓ due to liver disease
– Alcohol powerful inducer of microsomal enzymes (↑ NAPQ production)
• Acetaminophen overdose (15g) is a medical emergency
– 90% pts develop hepatotoxicity with centrilobular necrosis
– sometimes renal tubular necrosis & hypoglycemia → coma
– Gastric lavage with activated charcoal prevents further absorption
but ineffective after 4 hrs of ingestion
– ↓ by N acetylcystine (replenishes glutathione stores of liver)
• Common OTC analgesic for headache, mild migraine,
musculoskeletal pain
25. Situation NSAID
Mild to moderate pain with little
inflammation
Paracetamol or low dose ibuprofen
Post operative or short lasting pain Ketorolac, Ibuprofen, Diclofenac,
Nimesulide
Acute musculoskeletal, osteoarthritic,
injury pain
Paracetamol, Ibuprofen Or Diclofenac
RA, Ankylosing spondylitis, acute gout,
acute rheumatic fever
Naproxen, Piroxicam, Indomethacin,
high dose Aspirin
Gastric intolerance to traditional NSAIDs Selective Cox 2 inhibitor or Paracetamol
Pts with history of asthma or
anaphylactoid reaction to NSAIDs
Nimesulide or Cox 2 inhibitor
Pediatric patients Paracetamol, Ibuprofen and Naproxen
Pregnancy Paracetamol safest, low dose Aspirin
second best
26.
27. SUMMARY
All NSAIDS are weak acids except nabumetone.
All NSAIDs are racemic mixtures
except naproxen (present as single enantiomer) and
diclofenac (have no chiral center)
Sulindac and nabumetone are prodrugs. Piroxicam
and tenoxicam are longest acting NSAIDs due to
enterohepatic cycling.
All NSAIDs are almost equally efficacious except–
Aspirin is less effective for ankylosing spondylitis
28. SUMMARY
Paracetamol (acetaminophen) has no anti-inflammatory
activity
Nimesulide and nefopam: do not act by decreasing Pg
synthesis
Ketorolac is the only NSAID that can be used i.v.
– Aspirin is contraindicated inchildren (<12 yrs old) due to
increased risk of Reye’s syndrome
- Nephrotoxicity and hepatotoxicity may occur with any
NSAID.
Rofecoxib and valdecoxib were withdrawn due to increased
risk of thrombotic disorders like myocardial infarction.